Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$17.38 USD
-0.33 (-1.86%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $17.38 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Fundamental Charts
About Return on Equity (TTM)
Arcutis Biotherapeutics, Inc.'s return on equity, or ROE, is -62.62% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that ARQT has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ARQT 17.38 -0.33(-1.86%)
Will ARQT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARQT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARQT
Are Medical Stocks Lagging AxoGen (AXGN) This Year?
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?
ARQT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?
Other News for ARQT
ARQT forms Three Weeks Tight on September 19
The technical outlook for ARQT is unchanged after it rises 3.33% on September 18
ARQT's price rises by 1.0% on September 17, though its technical setup remains stable.
Is ARQT primed for upward momentum? Non-ADX 1,2,3,4 Bullish shows up after rising 0.24%
Arcutis Biotherapeutics (ARQT) Unveils Positive Data on Zoryve Foam at Dermatology Congress